Loading clinical trials...
Loading clinical trials...
Hematopoietic Stem Cell Transplantation for Patients With Severe Sickle Cell Disease Using Myeloablative Conditioning and αβ+ T-cell Depleted Hematopoietic Stem Cells From Partially Matched Familial Donors
Conditions
Interventions
αβ+ T-cell depletion with Miltenyi CliniMACS system
Locations
1
United States
The University of Chicago
Chicago, Illinois, United States
Start Date
April 7, 2020
Primary Completion Date
May 22, 2023
Completion Date
May 22, 2023
Last Updated
December 4, 2024
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
University of Chicago
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions